R. Goldie (Adelaide, Australia), B. O'Connor (London, United Kingdom)
Efficacy of antiepileptic drugs diphenine and carbamazepine in pharmacotherapy of children with bronchial asthma: is asthma a neurogenic inflammatory disease?
M. Lomia, T. Tchelidze, M. Pruidze (Tbilisi, Georgia)
|  |
Indacaterol, a novel once-daily β2-agonist, is well tolerated in persistent asthma
W. Yang, M. Higgins, R. Cameron, R. Owen (Ottawa, Canada; Horsham, United Kingdom)
| |
Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma
P. Paggiaro, A. Papi, Y. I. Feschenko, G. Nicolini, L. M. Fabbri (Pisa, Ferrara, Parma, Modena, Italy; Kiev, Ukraine)
| |
Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone
P. Kuna, M. J. Peters, R. Buhl (Lodz, Poland; Concord, Australia; Mainz, Germany)
| |
Lower systemic exposure to corticosteroid for fluticasone propionate/salmeterol (500/50mcg bd) compared to budesonide/formoterol (400/12mcg bd) administered via combination dry powder inhalers in subjects with COPD
A. Cahn, A. Allen, P. Russell, F. Petavy, A. Williams, R. Fuhr, P. T. Daley-Yates (Greenford, Llantrisant, United Kingdom; Berlin, Germany)
| |
Beclometasone diproprionate/formoterol in a single inhaler improves lung function and clinically meaningful outcomes in moderate to severe asthma
F. Bonnet-Gonod, I. Kottakis, T. Hofman, L. Dymek, J. Bousquet (Courbevoie, Montpellier, France; Parma, Italy; Poznan, Strzelce Opolskie, Poland)
| |
Ciclesonide 160 μg once daily compared with fluticasone propionate 250 μg twice daily in maintenance therapy of patients with stable asthma
M. Adler, J. Langan, J. B. Martinot, L. Croonenborghs, C. Gruss, C. Oedekoven (Harrow, Glasgow, United Kingdom; Namur, Veurne, Belgium; Konstanz, Germany)
| |
Comparison of ciclesonide 160 versus 640 μg per day in patients with severe asthma
E. D. Bateman, G. Velazquez-Samano, L. Záková, A. Chuchalin, U. M. Göhring, R. Engelstätter (Cape Town, South Africa; Mexico City, Mexico; Prague, Czech Republic; Moscow, Russian Federation; Konstanz, Germany)
| |
Effects of ciclesonide on lung function and cortisol excretion in adolescent asthma patients – a comparative study with budesonide
J. H. Vermeulen, L. Kósa, J. R. Villa, H. Rauer, W. Wurst, R. Engelstätter (Cape Town, South Africa; Budapest, Hungary; Madrid, Spain; Konstanz, Germany)
| |
Efficacy and safety of ciclesonide compared with fluticasone propionate in patients with moderate to severe asthma
E. D. Bateman, J. P. Ketterer, W. R. Pieters, D. Dutchman, L. Smau, R. Engelstätter (Cape Town, South Africa; La Chaux-de-Fonds, Switzerland; Helmond, Netherlands; Hastings, United Kingdom; Konstanz, Germany)
| |
Efficacy of inhaled ciclesonide compared with oral prednisolone in the treatment of asthma exacerbations
D. S. Postma, S. H. Arshad, E. H. Hamelmann, M. van den Berge (Groningen, Netherlands; Stoke-on-Trent, United Kingdom; Berlin, Germany)
| |
Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma
E. Rigamonti, I. Kottakis, M. Pelc, I. Grzelewska Rzymowska, Y. Feschenko (Parma, Italy; Krakow, Lodz, Poland; Kiev, Ukraine)
| |
Superior efficacy of a low daily dose of a new fixed combination of beclometasone dipropionate/formoterol pMDI compared to an increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study
F. Bonnet-Gonod, I. Kottakis, M. Ballabio, J. Ruzicka, A. Savu, P. Kuna (Courbevoie, France; Parma, Italy; Bratislava, Slovakia; Bucharest, Romania; Lodz, Poland)
| |
Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma
S. Pascoe, L. J. Knowles, M. Glasbrenner, T. Duvauchelle, R. Fuhr, L. J. Brookman (Horsham, United Kingdom; Basel, Switzerland; Paris, France; Berlin, Germany)
| |
Reproducibility and patient acceptability of the inhaled corticosteroid questionnaire (ICQ): a patient self-reported side effect scale
J. M. Foster, E. van Sonderen, A. J. Lee, R. Sanderman, A. Dijkstra, D. S. Postma, T. van der Molen (Aberdeen, United Kingdom; Groningen, Netherlands)
| |
Levofloxacin prevents eosinophil activation and asthma exacerbation
K. Sugiyama, H. Sagara, K. Mashio, H. Takizawa, T. Ohara, T. Fukuda (Mibu, Japan)
| |
The effect of phosphogliv admission on non-invasive oxidative stress markers in patients with bronchial asthma
A. V. Lisitsa, S. K. Soodaeva, I. A. Klimanov, A. G. Chuchalin (Moscow, Russian Federation)
| |
Once daily ciclesonide delivered via pMDI is effective and safe for the treatment of mild-to-moderate persistent asthma
V. Singh, S. S. Salvi, B. B. Brashier, A. U. Athavale, V. B. Murali Mohan, P. S. Bhattacharya, P. M. Gokhale, P. A. Mahadik, J. A. Gogtay (Jaipur, Pune, Mumbai, Banglore, , Mumbai Central, India)
| |
The effect of inhaled budesonide and formoterol on bronchial remodeling in young asthmatics
F. Capraz, E. Kunter, A. Ilvan, H. Cermik, S. Pocan (Istanbul, Turkey)
| |
Responsiveness of the inhaled corticosteroid questionnaire (ICQ): a patient self-reported side effect scale
J. M. Foster, E. van Sonderen, A. J. Lee, R. Sanderman, A. Dijkstra, D. S. Postma, T. van der Molen (Aberdeen, United Kingdom; Groningen, Netherlands)
| |